␥-Aminobutyric acid, type B (GABA B ) receptors are heterodimeric G protein-coupled receptors that mediate slow inhibitory synaptic transmission in the central nervous system. To identify novel interacting partners that might regulate GABA B receptor (GABA B R) functionality, we screened the GAB-A B R2 carboxyl terminus against a recently created proteomic array of 96 distinct PDZ (PSD-95/Dlg/ZO-1 homology) domains. The screen identified three specific PDZ domains that exhibit interactions with GABA B R2: Mupp1 PDZ13, PAPIN PDZ1, and Erbin PDZ. Biochemical analysis confirmed that full-length Mupp1 and PAPIN interact with GABA B R2 in cells. Disruption of the GAB-A B R2 interaction with PDZ scaffolds by a point mutation to the carboxyl terminus of the receptor dramatically decreased receptor stability and attenuated the duration of GABA B receptor signaling. The effects of mutating the GABA B R2 carboxyl terminus on receptor stability and signaling were mimicked by small interference RNA knockdown of endogenous Mupp1. These findings reveal that GABA B receptor stability and signaling can be modulated via GABA B R2 interactions with the PDZ scaffold protein Mupp1, which may contribute to cell-specific regulation of GABA B receptors in the central nervous system.
GABA B2 receptors are G protein-coupled receptors responsible for mediating slow inhibitory synaptic transmission by the neurotransmitter GABA (1). They belong to G protein-coupled receptor Family C and bear a high degree of homology to other family members such as the metabotropic glutamate receptors, calcium receptor, and vomeronasal receptors. GABA B receptors are believed to be heterodimeric combinations of two G protein-coupled receptors, GABA B R1 and GABA B R2 (2-4). Heterodimerization of GABA B R1 and GABA B R2 is necessary for the proper trafficking of GABA B R1 to the cell surface (5, 6). In the context of the heterodimer, GABA B R1 is thought to bind the ligand (7), whereas GABA B R2 is believed to be the primary G protein contact site (8 -11).Given that GABA B receptors are important therapeutic targets for a wide variety of diseases, including depression, anxiety, epilepsy, and drug addiction (12, 13), understanding GABA B receptor signaling and regulation is of significant clinical interest. The cloning of the GABA B receptors has advanced the study of the GABA B receptors substantially over the past decade. However, some discrepancies between the properties of native GABA B receptors and heterologously expressed recombinant receptors still remain. For example, GABA B receptors in native tissue undergo robust endocytosis and desensitization (14), whereas recombinant GABA B R1/GABA B R2 expressed in most heterologous cells neither internalize nor desensitize (14, 15). One possible explanation for such discrepancies is that GABA B receptor signaling and trafficking properties are highly dependent on cellular context. This implies that interaction with differentially expressed cellular proteins might modulate GABA B receptor function. Indeed, we...